SCHEMBL4170192

SCHEMBL4170192

CCC(C)C(NCc1ccccc1)C(=O)OC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.55
ANPEP P15144 1/20 0.52
ALDH1A1 P00352 4/20 0.52
MAPT P10636 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
HTT P42858 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
POLB P06746 1/20 0.50
ELANE P08246 1/20 0.48
NOS3 P29474 1/20 0.47
NOS1 P29475 1/20 0.47
NOS2 P35228 1/20 0.47
CTSL P07711 1/20 0.47
CTSB P07858 1/20 0.47
CTSS P25774 1/20 0.47
ATM Q13315 1/20 0.46
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4166663 1.00 TRPM8 (0.55) TRPM8ANPEPALDH1A1MAPTL3MBTL1
SCHEMBL13915548 1.00 TRPM8 (0.55) TRPM8ANPEPALDH1A1MAPTL3MBTL1
SCHEMBL5658130 0.87 ANPEP (0.57) ANPEPALDH1A1MAPTMEN1KMT2A
SCHEMBL8069933 0.87 ANPEP (0.57) ANPEPALDH1A1MAPTMEN1KMT2A
SCHEMBL5658127 0.87 ANPEP (0.57) ANPEPALDH1A1MAPTMEN1KMT2A
SCHEMBL18782332 0.87 ANPEP (0.57) ANPEPALDH1A1MAPTMEN1KMT2A
SCHEMBL28322266 0.87 TRPM8 (0.54) TRPM8ANPEPALDH1A1MAPTL3MBTL1
SCHEMBL24326690 0.86 TRPM8 (0.59) TRPM8ANPEPALDH1A1MAPTL3MBTL1
SCHEMBL1889631 0.86 TRPM8 (0.59) TRPM8ANPEPALDH1A1MAPTL3MBTL1
SCHEMBL1889629 0.86 TRPM8 (0.59) TRPM8ANPEPALDH1A1MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12152048-B2 Nitroxoline prodrug and use thereof JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2024-11-26 US disclosed
US-20210363165-A1 NITROXOLINE PRODRUG AND USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2021-11-25 US disclosed
US-20210363165-A1 NITROXOLINE PRODRUG AND USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2021-11-25 US disclosed
EP-3858814-A1 NITROXOLINE PRODRUG AND USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2021-08-04 EP disclosed
EP-3858814-A1 NITROXOLINE PRODRUG AND USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2021-08-04 EP disclosed
CN-111295372-B Nitroxoline prodrugs and uses thereof 江苏亚虹医药科技股份有限公司 2021-03-09 CN disclosed
CN-111295372-A Nitroxoline prodrugs and uses thereof 江苏亚虹医药科技有限公司 2020-06-16 CN disclosed
WO-2020063824-A1 NITROXOLINE PRODRUG AND USE THEREOF 江苏亚虹医药科技有限公司 2020-04-02 WO disclosed
US-8552208-B2 Analogs of tetramic acid University of Tennesseee Research Foundation (US) 2013-10-08 US disclosed
US-20090069406-A1 Analogs of tetramic acid NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12152048-B2 Nitroxoline prodrug and use thereof NOS1, NOS2, NNT TRPM8 3143/4885ANPEP 796/4885ALDH1A1 706/4885
US-20210363165-A1 NITROXOLINE PRODRUG AND USE THEREOF NOS1, NOS2, NNT TRPM8 3143/4885ANPEP 796/4885ALDH1A1 706/4885
US-20090069406-A1 Analogs of tetramic acid TFRC, SLC7A1, FTH1 TRPM8 1477/4885ANPEP 948/4885ALDH1A1 2743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.